Supernus Pharmaceuticals, Inc.
SUPN
Rank in Stocks
#4230
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Share Price
$29.72
Last synced: 2026-11-13
Market Cap
$3.51B
Change (1 day)
1.78%
Change (1 year)
-34.09%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Supernus Pharmaceuticals, Inc. (SUPN)
Category
Healthcare
Dividend history for Supernus Pharmaceuticals, Inc. (SUPN)
Supernus Pharmaceuticals, Inc. (stock symbol: SUPN) made a total of 3 dividend payments.
The sum of all dividends (adjusted for stock splits) is : $8.77
Dividend yield (TTM) : 27.36%
The sum of all dividends (adjusted for stock splits) is : $8.77
Dividend yield (TTM) : 27.36%
Dividend payments for Supernus Pharmaceuticals, Inc. (SUPN) from 2015 to 2026
Annual dividend payments
| Year | Dividend (stock split adjusted) | Change |
|---|---|---|
| 2026 (TTM) | $8.13 | 1,611.58% |
| 2016 | $0.48 | 196.88% |
| 2015 | $0.16 | 0.00% |
List of all dividend payments
| Year | Dividend | Change |
|---|---|---|
| 2026 (TTM) | $8.13 | 8,457.89% |
| 2016 | $0.095 | 196.88% |
| 2015 | $0.032 | 0.00% |
Dividend payments for similar companies or competitors
| Company | Number of dividend payments | Country |
|---|---|---|
| 13.00% |
DE
|
|
| 26.00% |
DE
|
|
| 55.00% |
JP
|
|
| 2.00% |
CH
|
|
| 62.00% |
IL
|
Questions about Supernus Pharmaceuticals, Inc.'s dividend per share
What is Supernus Pharmaceuticals, Inc.'s dividend per share?
Supernus Pharmaceuticals, Inc.'s dividend per share over the last twelve months is $8.13, as of Nov 2026.
What was Supernus Pharmaceuticals, Inc.'s dividend per share in 2016?
In 2016, Supernus Pharmaceuticals, Inc.'s dividend per share was $0.48, 196.88% more than in 2015 ($0.16).